Related Experiment Video

Updated: May 24, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Mild cognitive impairment in Parkinson disease: heterogenous mechanisms

Kurt A Jellinger1

  • 1Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria. kurt.jellinger@univie.ac.at

Journal of Neural Transmission (Vienna, Austria : 1996)
|February 22, 2012
PubMed

Insights

Most Parkinson disease (PD) patients experience cognitive impairment, often progressing to dementia. Early diagnosis of mild cognitive impairment in PD (PD-MCI) is crucial for prognosis, despite diagnostic challenges.

Area of Science:

  • Neurology
  • Neuroscience
  • Cognitive Science

Background:

  • Cognitive impairment is a prevalent and progressive condition in Parkinson disease (PD).
  • A significant percentage of patients with mild cognitive impairment in PD (PD-MCI) transition to dementia.
  • Cognitive deficits in PD span multiple domains, with non-amnestic and single-domain impairments being more common.

Purpose of the Study:

  • To explore the biological validity and heterogeneity of mild cognitive impairment in Parkinson disease (PD-MCI).
  • To highlight the need for standardized diagnostic criteria for PD-MCI.
  • To emphasize the importance of early diagnostic and prognostic assessments for cognitive deficits in PD.

Main Methods:

  • Review of recent studies examining clinical presentation, neuropsychology, neuroimaging, biomarkers, and neuropathology in PD-MCI.
  • Analysis of metabolic network activities in cortical and subcortical nervous systems.
  • Discussion of the role of prospective studies with specific biomarkers.

Main Results:

  • Evidence supports the biological validity of PD-MCI, revealing heterogeneous underlying mechanisms.
  • Abnormal metabolic network activities involving multiple brain regions are implicated.
  • Lack of uniform diagnostic criteria for PD-MCI remains a challenge.

Conclusions:

  • Despite diagnostic controversies, PD-MCI represents a distinct clinical entity with diverse pathological underpinnings.
  • Further research utilizing advanced biomarkers, such as amyloid imaging and cerebrospinal fluid analysis, is essential.
  • Accurate diagnosis and prognostic assessment of early cognitive deficits in PD are critical for patient management.

More Related Videos

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...